Theravance Biopharma (NASDAQ:TBPH) reported Q2 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.5 million.
Theravance Biopharma (NASDAQ:TBPH) reported Q2 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.5 million.